Venomtech - Venom Research Solutions
Venomtech was founded in 2010 by Steve Trim to help solve one of the problems often encountered as a pharmaceutical scientist - finding adequate new drug leads.
We are a biotechnology company with a focus on developing novel venom-derived screening tools, and lead compounds. Our passion and drive for drug discovery is intrinsically linked to our desire to advance human healthcare and to our personal experience of the challenges in drug discovery. We use venoms from a range of vertebrate and invertebrate species including snakes, spiders and centipedes.
Our products and services address one of the most common frustrations in drug discovery: the failure to find promising drug candidates in available libraries of synthetic chemical molecules.
- A wide array of venoms, in sufficient quantities for repeated experiments, to obtain consistent results.
- Many proprietary skills and unique technical facilities to extract venoms.
- Developed a systematic approach that involves separating venoms into smaller, simpler fractions, providing researchers with targeted high-quality venom preparations in a ready to use format.
Collections of new and promising compounds, such as venoms, increase the likelihood of finding effective, unique and high-value drug candidates for difficult targets.
Venomtech specialises in this field, and has made venom array sales to major pharmaceutical customers across the world, including North America, Japan and Europe.
Steve Trim BSc, CBiol, MRSB
Founder/ CSO/ General Manager
Steve spent a decade working as a molecular biologist in drug discovery at Pfizer, working extensively on pain therapeutics and developing expertise in the tissue repair, gastrointestinal and respiratory fields. Having worked across molecular biology, pharmacology, biochemistry and anatomy, Steve has a deep understanding of drug discovery and the use of venoms and toxins in this area. Drawing on this experience, he founded Venomtech with the goal of solving the problems the industry faces in finding new medicines.
Professor Karol Sikora, MA, MBBChir, PhD, MD, FRCR, FRCP, FRCPE, FFPM
Karol is a consultant 0ncologist at Hammersmith Hospital, London, medical director of Proton Partners International and dean of the University of Buckingham's medical school. He launched CancerPartnersUK, Britain's largest independent network of innovative cancer treatment centres. He was Chief of the World Health Organisation's Cancer Programme between 1997 and 1999 and has been an adviser to the UN's International Atomic Energy Agency. Karol provides invaluable expertise in oncology and therapeutics.
Doctor Paul Grant MSc. PhD
Paul has 10 years of experience in academic research, including time spent at Kings College London and St. Georges Hospital, London, as well as 12 years experience in drug discovery business development. In this time, he has developed deep industry knowledge, contacts and scientific credibility. Paul has worked with major pharmaceutical, biotechnology, academic, CRO and diagnostic companies across Europe, USA and Asia.